BR112015032211A2 - Método para monitorar resposta à inibição de hsp90, e, uso de um polipeptídeo isolado conjugado com 18f - Google Patents

Método para monitorar resposta à inibição de hsp90, e, uso de um polipeptídeo isolado conjugado com 18f

Info

Publication number
BR112015032211A2
BR112015032211A2 BR112015032211A BR112015032211A BR112015032211A2 BR 112015032211 A2 BR112015032211 A2 BR 112015032211A2 BR 112015032211 A BR112015032211 A BR 112015032211A BR 112015032211 A BR112015032211 A BR 112015032211A BR 112015032211 A2 BR112015032211 A2 BR 112015032211A2
Authority
BR
Brazil
Prior art keywords
isolated polypeptide
hsp90 inhibition
conjugated
polypeptide conjugated
monitoring response
Prior art date
Application number
BR112015032211A
Other languages
English (en)
Inventor
Robert R Hiscock Duncan
Aboagye Eric
Iveson Peter
Nguyen Quang-De
Hoppmann Susan
Trousil Sebastian
Kaliszczak Maciej
Tomasi Giampaolo
Original Assignee
Ge Healthcare Ltd
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd, Imperial Innovations Ltd filed Critical Ge Healthcare Ltd
Publication of BR112015032211A2 publication Critical patent/BR112015032211A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

MÉTODO PARA MONITORAR RESPOSTA À INIBIÇÃO DE HSP90, E, USO DE UM POLIPEPTÍDEO ISOLADO CONJUGADO COM 18F. Um método para uso de um polipeptídeo isolado conjugado com um radionuclídeo, em que o polipeptídeo isolado se liga especificamente ao HER2, ou uma variante do mesmo é descrito. O método é para monitorar a resposta à inibição de HSP90 e compreende o uso do polipeptídeo isolado conjugado com 18F. A aplicação também descreve o uso de um polipeptídeo isolado conjugado com 18F, em que o polipeptídeo isolado se liga especificamente ao HER2 ou variantes da mesma, como um agente de formação de imagem para monitorar a captação da mesma para medir a inibição de HSP90.
BR112015032211A 2013-06-27 2014-06-24 Método para monitorar resposta à inibição de hsp90, e, uso de um polipeptídeo isolado conjugado com 18f BR112015032211A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840021P 2013-06-27 2013-06-27
PCT/SE2014/050774 WO2014209205A1 (en) 2013-06-27 2014-06-24 Use of her2 binders

Publications (1)

Publication Number Publication Date
BR112015032211A2 true BR112015032211A2 (pt) 2017-08-29

Family

ID=52142378

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015032211A BR112015032211A2 (pt) 2013-06-27 2014-06-24 Método para monitorar resposta à inibição de hsp90, e, uso de um polipeptídeo isolado conjugado com 18f

Country Status (7)

Country Link
US (1) US10646600B2 (pt)
EP (1) EP3014277A4 (pt)
JP (1) JP2016526556A (pt)
KR (1) KR20160055728A (pt)
CN (1) CN105579851A (pt)
BR (1) BR112015032211A2 (pt)
WO (1) WO2014209205A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3014277A4 (en) 2013-06-27 2017-04-19 GE Healthcare Limited Use of her2 binders
EP3643726A4 (en) * 2017-06-20 2021-09-01 Nanomab Technology Limited ANTI-HER2 NANOCBODIES, CODING SEQUENCE AND ASSOCIATED USE
CN108434469A (zh) * 2018-05-29 2018-08-24 江苏省原子医学研究所 一种HER2亲合体的68Ga标记物及其制备方法、应用
CN110251695B (zh) * 2019-07-10 2021-12-21 莎穆(上海)生物科技有限公司 一种靶向her2的放射性配合物及其制备方法和应用
CN114317385B (zh) * 2021-11-11 2024-02-13 元本(珠海横琴)生物科技有限公司 一种促进her2亲和体蛋白分泌表达的发酵培养基及发酵工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007024940A2 (en) * 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
WO2008118601A2 (en) * 2007-02-27 2008-10-02 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Radiolabeled affibody molecules
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
US20120165650A1 (en) * 2010-12-22 2012-06-28 General Electric Company Her2 binders
SG173812A1 (en) * 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
US20150283272A1 (en) * 2010-10-27 2015-10-08 Vikas Kundra Dual mode gadolinium nanoparticle contrast agents
RU2013128360A (ru) * 2010-12-22 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Her2-связывающие белки, меченые 18f-содержащим кремнийорганическим соединением
KR102498607B1 (ko) * 2010-12-22 2023-02-13 제너럴 일렉트릭 캄파니 방사성표지 ｈｅｒ２ 결합 펩티드
EP3014277A4 (en) 2013-06-27 2017-04-19 GE Healthcare Limited Use of her2 binders

Also Published As

Publication number Publication date
EP3014277A1 (en) 2016-05-04
CN105579851A (zh) 2016-05-11
WO2014209205A1 (en) 2014-12-31
KR20160055728A (ko) 2016-05-18
JP2016526556A (ja) 2016-09-05
EP3014277A4 (en) 2017-04-19
US10646600B2 (en) 2020-05-12
US20160144062A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CO2017001994A2 (es) Compuestos activos hacia bromodominios
BR112015031475A2 (pt) composto, composição farmacêutica, método para tratamento de uma doença ou condição, kit, e, uso de composto.
BR112015032211A2 (pt) Método para monitorar resposta à inibição de hsp90, e, uso de um polipeptídeo isolado conjugado com 18f
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
CR20160199A (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
BR112017010414A2 (pt) métodos e composições para radiomarcação com 18f de substâncias biológicas
BR112015021352A2 (pt) composições antimicrobianas
BR112016004415A2 (pt) método de tratamento de um paciente diagnosticado com um glioblastoma, uso de uma quantidade eficaz de um anticorpo anti-vegf, composição e kit
BR112012015147A2 (pt) conjugado de complexo de agente e pelo menos um ligante localizador de alvo, análogo de prostaciclina, e, composição terapêutica para o tratamento de distúrbios pulmonares
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
BR112018073642A2 (pt) imunomoduladores para imagiologia tep
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112015016585A2 (pt) Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
BR112016013502A2 (pt) unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2015000615A1 (es) Compuestos derivados de 4-amino-quinolinas, inhibidores de rip2 cinasa; composicion farmaceutica que los comprende; uso para el tratamiento de enfermedades tales como enfermedad de crohn, colitis ulcerativa o sindrome de blau.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016007620A2 (pt) composto, medicamento, e, uso de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2435 DE 05-09-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.